New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Kryxana 200 Mg (Ribociclib Tablets)

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

  • Generic Brand Name- Kryxana
  • API- Ribociclib
  • Strength- 200 mg
  • Packaging- 21 Tablets
  • Manufacturer Name- Novartis Pharma

South Delhi Pharma can facilitate the supply of “Kryxana (Ribociclib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Kryxana (Ribociclib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.


Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Kryxana is?

Kryxana 200 mg (Ribociclib) is a cyclin-dependent kinase inhibitor, indicated to use with the combination of the aromatase inhibitor to treat HR-Positive and HER2-Negative advanced as well as metastatic breast cancer. This FDA approved medication was developed by Novartis.

What Ribociclib is?

Ribociclib was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the European Medicines Agency (EMA) in August 2017, for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers.

Ribociclib, sold under the brand name Kisqali, is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.

Related Products